About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Taking 160 milligrams of aspirin a day cuts the risk of cancer recurrence in half among colon cancer patients with a mutation in their PI3K genes, researchers reported at the 2025 American Society of ...